WASHINGTON — An experimental vaccine against the coronavirus showed encouraging results in very early testing, triggering hoped-for immune responses in eight healthy, middle-aged volunteers, its maker announced Monday.
Study volunteers given either a low or medium dose of the vaccine by Cambridge, Massachusetts-based Moderna Inc. had antibodies similar to those seen in people who have recovered from COVID-19.
In the next phase of the study, led by the U.S. National Institutes of Health, researchers will try to determine which dose is best for a definitive experiment that they aim to start in July.
In all, 45 people have received one or two shots of the vaccine, which was being tested at three different doses. The kind of detailed antibody results needed to assess responses are only available on eight volunteers so far.
The vaccine seems safe, the company said, but much more extensive testing is needed to see if it remains so. A high dose version is being dropped after spurring some short-term side effects.
The results have not been published and are only from the first of three stages of testing that vaccines and drugs normally undergo. U.S. government officials have launched a project called “Operation Warp Speed” to develop a vaccine and hopefully have 300 million doses by January.
Worldwide, about a dozen vaccine candidates are in the first stages of testing or nearing it. Health officials have said that if all goes well, studies of a potential vaccine might wrap up by very late this year or early next year.
More than 4.7 million infections and 315,000 deaths from the coronavirus have been confirmed worldwide since it emerged in China late last year. There are no specific approved treatments, although several are being used on an emergency basis after showing some promise in preliminary testing.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
GLOBAL GATHERING RECOMMENDS
WASHINGTON (AP) — Former President Barack Obama on Saturday criticized U.S. leaders overseeing the nation’s response to the coronavirus, telling college graduates in an online commencement address that the pandemic shows many officials “aren’t even pretending to be in charge.” Obama spoke on “...
NEW YORK (AP) — New York City’s death toll from the coronavirus may be thousands of fatalities worse than the tally kept by the city and state, according to an analysis released Monday by the U.S. Centers for Disease Control and Prevention. Between March 11 and May 2, about 24,000 more people ...
The coronavirus pandemic is straining social safety nets across the globe — and underlining sharp differences in approach between wealthy societies such as the United States and Europe. In Europe, the collapse in business activity is triggering wage support programs that are keeping millions ...
WASHINGTON (AP) — The U.S. unemployment rate rocketed to 14.7% in April, a level last seen during the Great Depression, as 20.5 million jobs vanished in the worst monthly loss on record — stark evidence of how the coronavirus has brought the economy to its knees.
WASHINGTON (AP) — Hundreds of people are rolling up their sleeves in countries across the world to be injected with experimental vaccines that might stop COVID-19, spurring hope — maybe unrealistic — that an end to the pandemic may arrive sooner than anticipated. About 100 research groups are...
LONDON (Reuters) - Britain will trial a new coronavirus tracing programme next week on the Isle of Wight, just off the south coast of England, cabinet minister Michael Gove said on Sunday as the government looks at how to minimise the risk of a second wave of infection. Suffering one of the w...
WASHINGTON (AP) — U.S. regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster. It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide. President Donald Trump announced...